Table 4 AURKA is associated with metastasis-free survival (MFS) in three independent cohorts of systemically untreated node negative breast cancer (combined Mainz, Rotterdam and Transbig cohorts, n=766)
Mainz cohort (n=200) | Rotterdam cohort (n=286) | Transbig cohort (n=280) | Combined cohorts (n=766) | ||
|---|---|---|---|---|---|
A. Univariate Cox analysis | |||||
AURKA | P-value | <0.001 | <0.001 | 0.005 | <0.001 |
HR | 1.927 | 1.952 | 1.520 | 1.669 | |
95%-CI | 1.335-2.782 | 1.448-2.632 | 1.135-2.036 | 1.402-1.986 | |
B. Multivariate Cox analysis of MFS adjusted to established clinical factors (combined Mainz and Transbig cohorts, n=465) | |||||
p | HR | 95 % CI | |||
Age (<50 vs. ≥50 years) | 0.392 | 1.180 | 0.808-1.726 | ||
pT stage (≤2cm vs. >2cm) | 0.005 | 1.812 | 1.192-2.754 | ||
Histological grade (Grade 1 and 2 vs. grade 3) | 0.087 | 1.529 | 0.940-2.487 | ||
ER status (negative vs. positive) | 0.413 | 1.214 | 0.763-1.931 | ||
HER2 status (negative vs. positive) | 0.415 | 1.248 | 0.732-2.128 | ||
AURKA (continuous variable) | 0.046 | 1.350 | 1.005-1.812 | ||